Aurobindo, Sandoz call off $900 million deal

Aurobindo Pharma has said the $900 million deal to acquire Sandoz Inc’s US-based generic oral solids and dermatology businesses, has been mutually called off.

"The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines," Aurobindo Pharma said in a regulatory filing.

In September 2018, Aurobindo Pharma had said its US subsidiary has entered into a pact to acquire commercial operations and three manufacturing facilities in America from Sandoz Inc, USA, for $900 million.

The acquisition was to be made through its wholly-owned subsidiary, Aurobindo Pharma USA Inc.

The transaction, if completed, would have positioned the Hyderabad-based firm as the second largest dermatology player and the second largest generics company in the US by prescriptions.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.